Patients with HER2-mutant breast cancer given neratinib combinations saw improved efficacy.
Paolo Tarantino, MD, hosted a Twitter Takeover during the San Antonio Breast Cancer Symposium where he discussed abstract presentations and key takeaways in a #CNRealTimeReport.
Research from the 2021 San Antonio Breast Cancer Symposium suggests pathologic complete response and event-free survival were not significantly impacted by race for women with high-risk breast cancer who underwent targeted neoadjuvant chemotherapy.
Patients with gremlin BRCA1/2 mutations and high-risk HER2-negative early breast cancer can have amenable adverse effects after being treated with chemotherapy before utilize olaparib.
Investigators were able to identify breast cancer immunohistochemistry markers including Ki-67, estrogen receptor, and progesterone receptor status utilizing deep learning–based artificial intelligence algorithms
Patients with hormone receptor-positive breast cancer who were treated with samuraciclib plus fulvestrant saw tumor activity.
Circulating tumor DNA should be utilized early to help detect relapse in patients with triple-negative breast cancer.
Second-line fam-trastuzumab deruxtecan-nxki prolonged survival and led to higher responses over ado-trastuzumab emtansine for patients with HER2-positive metastatic breast cancer.
Patients with HER2-positive breast cancer appeared to derive a higher overall survival benefit after being treated with pyrotinib plus capecitabine vs lapatinib plus capecitabine.
Utilizing neratinib or abo-trastuzumab emtansine for patients with HER2-positive early stage breast cancer reduced the risk of distant recurrence.